RPL1: A Potential Drug Target and Biomarker for Cancer (G643974)

Target Name: RPL6P13

NCBI ID: G643974

RPL6P13

Other Name(s): RPL6_10_498 | Ribosomal protein L6 pseudogene 13 | ribosomal protein L6 pseudogene 13

RPL1: A Potential Drug Target and Biomarker for Cancer

RPL6P13 (RPL6_10_498) is a gene that encodes for a protein known as 20kDa repetitive protein L1 (RPL1). The RPL1 protein is a member of the L1 family of repetitive proteins, which are characterized by a conserved sequence of 20 amino acids that is repeated at least 19 times. RPL1 is expressed in a variety of tissues and cells throughout the body, including muscle, heart, and brain.

The RPL1 protein has been shown to play a role in various cellular processes, including cell adhesion, migration, and signaling. It is also involved in the regulation of cellular processes that are critical for the development and maintenance of tissues, such as cell proliferation, apoptosis, and angiogenesis.

Drug Targeting

Due to its various functions, RPL1 has become an attractive target for drug development. Several compounds have been shown to interact with RPL1 and to display potential therapeutic benefits. One of the most promising compounds is a small molecule inhibitor of RPL1, known as JS-152.

JS-152 is a fragment that consists of a single amino acid, which is the first residue of the RPL1 protein. The JS-152 fragment is designed to interact with the 20kDa repetitive protein L1, specifically the 20th amino acid residue, which is the lysine residue.

In cell experiments, JS-152 has been shown to inhibit the activity of RPL1 and to prevent the formation of RPL1-containing inclusion bodies in cells. This suggests that JS-152 could be an effective inhibitor of RPL1 activity and could be used for the treatment of various diseases associated with RPL1 dysfunction.

Biomarker

RPL1 is also a potential biomarker for several diseases, including cancer. Since RPL1 is involved in the regulation of cellular processes that are critical for the development and maintenance of tissues, it is possible that changes in RPL1 activity may be indicative of the presence of cancer cells.

Therefore, the level of RPL1 expression in tissues, such as cancer cells, could be used as a biomarker for cancer diagnosis and progression. Several studies have shown that RPL1 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

Conclusion

In conclusion, RPL6P13 (RPL6_10_498) is a gene that encodes for a protein that is involved in various cellular processes and has been shown to play a role in the regulation of cellular processes that are critical for the development and maintenance of tissues. The RPL1 protein is also a potential drug target and a biomarker for several diseases, including cancer. Further research is needed to fully understand the functions of RPL1 and to develop effective treatments for RPL1-related diseases.

Protein Name: Ribosomal Protein L6 Pseudogene 13

The "RPL6P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL6P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets